Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ATTAIN-J (Japan)

ATTAIN-J (Japan)

Orforglipron · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
obesity
Official title
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-07 → 2025-06
Participants
238
Duration
72 weeks
Registry
NCT05931380

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 6 mgobesity7261—−5.9 % vs −0.6 %
Δ −5.3 pp
———————verified
orforglipron 12 mgobesity7257—−8.7 % vs −0.6 %
Δ −8.1 pp
———————verified
orforglipron 36 mgobesity7260—−7.9 % vs −0.6 %
Δ −7.3 pp
———————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (3)
  • orforglipron 6 mg · weight_tp · Abstract, Findings
    mean percentage change in bodyweight was -5·9% (95% CI -7·6 to -4·2) with orforglipron 6 mg
  • orforglipron 12 mg · weight_tp · Abstract, Findings
    -8·7% (-10·9 to -6·5) with 12 mg
  • orforglipron 36 mg · weight_tp · Abstract, Findings
    and -7·9% (-10·0 to -5·8) with 36 mg

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ATTAIN-J (Japan). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-j/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.